Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

689P - Effects of durvalumab-metformin on head and neck squamous cell carcinoma (HNSCC) as revealed by digital spatial profiling (DSP)

Date

10 Sep 2022

Session

Poster session 10

Topics

Cancer Biology;  Tumour Immunology;  Multi-Disciplinary and Multi-Professional Cancer Care;  Immunotherapy

Tumour Site

Head and Neck Cancers

Presenters

Jacob Riordan

Citation

Annals of Oncology (2022) 33 (suppl_7): S295-S322. 10.1016/annonc/annonc1056

Authors

J. Riordan1, A. Linnenbach2, A. Alnemri1, R. Philips1, S. Awosanya1, S. Sussman1, A. Luginbuhl1, D. Cognetti1, L. Harshyne3, M. Mahoney2, A. South2, D. Whitaker-Menezes3, M. Tuluc4, A. Argiris3, U. Martinez-Outschoorn3, J.M. Johnson3, J.M. Curry1

Author affiliations

  • 1 Otolaryngology - Head And Neck Surgery, Thomas Jefferson University, 19107 - Philadelphia/US
  • 2 Dermatology And Cutaneous Biology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 3 Medical Oncology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 4 Pathology, Thomas Jefferson University, 19107 - Philadelphia/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 689P

Background

The combination therapy durvalumab (anti PD-L1) plus metformin (oral anti-hyperglycemic) targets multiple facets of the immunosuppressive tumor microenvironment (TME) in HNSCC to promote anti-tumor immunity. Characterization of the TME is crucial for understanding tumor-immune interactions underlying effective therapies.

Methods

Eight responders (two major and six minor; pathologic response at primary site) from the durvalumab-metformin window of opportunity trial (NCT03618654) were selected for DSP analysis of RNA expression by using Nanostring’s GeoMx platform. Unbiased gene set enrichment analysis (GSEA) of expressed genes was performed by query with >22,000 gene sets encompassing cell type signatures, canonical pathways, and biologic processes. On-treatment effects were observed by longitudinal post- vs. pre-treatment contrast for all GSEA runs.

Results

Two independent GeoMx DSP runs revealed corroborating gene sets in cell type signature and gene ontology collections. In the stromal segment, treatment enriched the following gene sets: dendritic cells (normalized enrichment score (NES) >3.63; FDR q-value (q) = 0.0), Kupffer cells (NES >3.53; q = 0.0), microglia (NES >3.47; q = 0.0), macrophages (NES >3.38; q = 0.0), and antigen processing and presentation (NES >2.85; q = 0.0). In the tumor segment, treatment depleted a multicancer invasive signature in three patients (two major and one minor responder) (NES -2.50; q = 0.0). The leading edge of this invasive signature was replete with known cancer-associated fibroblast markers.

Conclusions

GeoMx DSP/GSEA of Durvalumab-metformin combination therapy is consistent with the enrichment of antigen-processing and presentation by macrophages and dendritic cells in the stromal segment of HNSCC. Simultaneously, therapy depletes the invasive signature of the tumor segment.

Clinical trial identification

NCT03618654.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

AstraZeneca.

Disclosure

D. Cognetti: Financial Interests, Personal, Other, Honoraria: Intuitive Surgical; Financial Interests, Personal, Advisory Role: Rakuten Medical. M. Mahoney: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb Foundation (I); Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb Foundation (I); Financial Interests, Personal, Royalties: Bristol Myers Squibb Foundation (I). A. South: Financial Interests, Personal, Stocks/Shares: Krystal Biotech, Zikani Therapeutics; Financial Interests, Personal, Advisory Role: Zikani Therapeutics; Financial Interests, Personal, Funding: Zikani Therapeutics. A. Argiris: Financial Interests, Personal, Advisory Role: Aspyrian Therapeutics, Bristol Myers Squibb, Debiopharm Group, Merck Serono, Roche, Seattle Genetics; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Merck Serono; Financial Interests, Personal, Funding: Bristol-Myers Squibb, Genentech/Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Serono. J.M. Johnson: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb, Foundation Medicine, Rakuten Medical; Financial Interests, Personal, Funding: AstraZeneca, Bristol Myers Squibb, Merck; Non-Financial Interests, Personal, Other, Uncompensated Relationship: Taproot Health Inc. J.M. Curry: Financial Interests, Personal, Advisory Role: Rakuten Medical, Sanofi; Financial Interests, Personal, Funding: AstraZeneca, Castle Biosciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.